Longer-Acting Formulations: Efforts to develop even longer-acting versions of semaglutide that could be administered less frequently than once weekly are underway, which could further improve patient compliance and quality of life
In the meantime, Mounjaro at 22.5% average weight loss remains the strongest licensed option available and produces results that, until recently, would also have seemed impossible. TRIUMPH-1 Extension: Results to 104 Weeks A pre-specified blinded extension of TRIUMPH-1 followed 532 participants with a baseline BMI of 35 or higher who completed the main 80-week study
The drug manufacturers often have patient support promotions that can be applied to assist with this monthly cost as well
We also ensure patients with contraindications, such as severe kidney disease or thyroid cancer, are fully informed
In the GLP-1 RA vs SGLT-2 inhibitor cohort, there was no difference in the adjusted HR of suicide or suicide attempts between patients treated with GLP-1 RAs compared with patients treated with SGLT-2 inhibitors after 1 year of follow-up (HR 365 0.93 [0.57;1.52]), see Table 2
So far, the literature hasn't raised major alarms, but the data is still nascent
